NCT01691924已完成1 期
Randomized, Double Blind, Placebo Controlled "First In-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau2 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 56
- 试验地点
- 2
- 主要终点
- Number of Adverse Events
研究概览
简要总结
No clinical trials with PBF-509 in humans have been performed to date. Only preclinical studies have been done to assess the pharmacology and pharmacokinetics, the safety and the toxicological profile of the PBF-509.
An initial testing of PBF-509 in humans is planned, starting with the first-into-man clinical trial where a single oral, dose-escalating, and placebo-controlled design will be implemented.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Each subject must meet all of the following inclusion criteria at the pre-study screening visit (within 4 weeks prior to dosing) in order to participate in this study.
- •Healthy male subjects, 18-45 years of age.
- •Clinically acceptable blood pressure and pulse rate in supine and standing position. Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.
- •Body weight within normal range (Quetelet's index between 19 and 26) expressed as weight (kg) / height (m2)..
- •Non-smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the administration of the study medication).
- •Able to understand the nature of the study and comply with all their requirements.
- •Free acceptance to participate in the study by obtains signed informed consent form approved by the Ethics Committee of the Hospital (CEIC).
排除标准
- •History of serious adverse reactions or hypersensitivity to any drug.
- •Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
- •Background or clinical evidence of chronic diseases.
- •Acute illness two weeks before drug administration.
- •Having undergone major surgery during the previous 6 months.
- •History of alcohol or drug abuse in the last 5 years.
- •Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
- •Need of any prescription medication within 14 days prior to the administration of the drug and non prescription medication or herbal medicines within 7 days prior to the administration of the drug.
- •Participation in other clinical trials during the previous 90 days in which an investigational drug or a commercially available drug was tested.
- •Not having donated blood during 3 month period before inclusion in the study.
- •Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.
- •12 lead ECG obtained at screening with PR > 220 msec, QRS>120 msec and QTc >440 msec, bradycardia (<50 bpm) or clinically significant minor ST wave changes or any other abnormal changes on the screening ECG.
- •Symptoms of a significant somatic or mental illness in the four week period preceding drug administration.
- •History of hepatitis B and / or C and / or positive serology results which indicate the presence of hepatitis B and / or C.
- •Positive results from the HIV serology.
- •Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation.
- •Positive results of the drug screening the day before starting treatment period.
- •Known hypersensitivity to the study drug or the composition of the galenical form
- •History of psychiatric diseases or epileptic seizures
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo capsules: solid microcrystalline cellulose c.s.p
干预措施: Placebo (Drug)
PBF-509
Experimental
The initial dose-escalation scheme includes the following eight doses: 10 mg, 20 mg, 40 mg,80 mg, 160 mg, 320 mg, 480 mg and 620 mg. This dose-escalation scheme has been built with the aim to reach the Minimum Intolerated Dose (MID), i.e. when investigator should stop escalating, and consequently the MTD.
干预措施: PBF-509 (Drug)
结局指标
主要结局
Number of Adverse Events
时间窗: 5-7 days post-dose
Safety and Tolerability evaluation
次要结局
- Pharmacokinetic profile analysis(0-24 h post dose)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)NCT02403193Palobiofarma SL92
已完成
1 期
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy VolunteersParkinson DiseaseNCT02111330Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau16
终止
1 期
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative ColitisUlcerative ColitisNCT05549323Pfizer44
已完成
2 期
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor SymptomsVasomotor SymptomsMenopauseNCT05312567Fervent Pharmaceuticals105
已完成
3 期
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in NarcolepsyNarcolepsyExcessive Daytime SleepinessCataplexySleep DisordersNCT01067222Bioprojet110